Developer of artificial intelligence-based medicine for gastroenterology designed for optimizing clinical trials investi
Developer of artificial intelligence-based medicine for gastroenterology designed for optimizing clinical trials investigating the treatment of inflammatory bowel disease (IBD).
QuantLogix's current estimate for Iterative Scopes, published 2026-09-27 — in line with the last disclosed round of $700M (2022-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$700M
2022-Q1
weight 0.04
How this price has held up
No round has priced for Iterative Scopes since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Iterative Scopes, 2026-09-27 (8167ca05658dff9e).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Iterative Scopes going public?
No. Iterative Scopes is private and has not filed to go public. There is no S-1 on file.
What is Iterative Scopes' valuation in 2026?
Iterative Scopes is valued at $700M as of 2022-Q1, set by its Series B ($150M, Jan 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Iterative Scopes filed an S-1?
No public S-1 is on file for Iterative Scopes.
How much has Iterative Scopes raised?
Iterative Scopes has raised $194.05M in total, most recently a Series B of $150M in Jan 2022.
Is Iterative Scopes publicly traded — can you buy Iterative Scopes stock?
No. Iterative Scopes is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Iterative Scopes on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2017
HQ
Cambridge, MA
Employees
250
Total Raised
$194.05M
Last Round
Series B — $150M (Jan 2022)
IPO Status
private
Fundraising Status
Series B · $150M · 4y 8mo ago
privateTotal raised $194.05M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$150M
Jan 2022
—
$700M
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
54
via greenhouse
Product-build share
69%
engineering, research, product, design
Trajectory
steady
heavy product build — 69% of open roles are product-building functions (engineering/research/product) — 30 of 54 open roles are research.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Clinical Data SpecialistClinical Research Coordinator IIClinical Research Coordinator IIClinical Research Coordinator IIClinical Research Coordinator IIClinical Research Coordinator II
Counted from Iterative Scopes's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q1. Refreshed quarterly.